AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2024

May 7, 2024

30610_dirs_2024-05-07_b4f18cda-7fbd-4711-b61c-a4fe80d55f02.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2024-05-06

Reporting Person: Nader Francois (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-06	Stock Option (Right to Buy)	$122.13	A	7557	Acquired	2034-05-06	Common Stock (7557)	Direct

Footnotes

F1: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.